Lineage Cell TherapeuticsLCTX
Market Cap: $158M
About: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Employees: 75
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
0.21% more ownership
Funds ownership: 49.8% [Q1] → 50.01% (+0.21%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
3% less funds holding
Funds holding: 116 [Q1] → 112 (-4) [Q2]
32% less capital invested
Capital invested by funds: $139M [Q1] → $94.2M (-$44.8M) [Q2]
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Craig-Hallum Albert Lowe 33% 1-year accuracy 1 / 3 met price target | 378%upside $4 | Buy Initiated | 20 Aug 2024 |